KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Capital Expenditures (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Capital Expenditures for 13 consecutive years, with $318000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 59.39% to $318000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $799000.0, a 74.02% decrease, with the full-year FY2025 number at $799000.0, down 74.02% from a year prior.
  • Capital Expenditures was $318000.0 for Q4 2025 at Xenon Pharmaceuticals, up from $281000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.2 million in Q1 2023 to a low of $43000.0 in Q1 2025.
  • A 5-year average of $721750.0 and a median of $459000.0 in 2021 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 940.57% in 2023; the steepest drop was 95.55% in 2023.
  • Xenon Pharmaceuticals' Capital Expenditures stood at $514000.0 in 2021, then surged by 240.86% to $1.8 million in 2022, then tumbled by 95.55% to $78000.0 in 2023, then surged by 903.85% to $783000.0 in 2024, then plummeted by 59.39% to $318000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Capital Expenditures are $318000.0 (Q4 2025), $281000.0 (Q3 2025), and $157000.0 (Q2 2025).